Literature DB >> 11751787

Comparative in vitro activity of ABT-773 and two macrolides against staphylococci.

Christof von Eiff1, Georg Peters.   

Abstract

The anti-staphylococcal activity of ABT-773, a new member of the ketolides, was examined and compared with those of erythromycin and clarithromycin using the agar dilution method. A total of 336 well-defined clinical isolates of staphylococci, including a large number of clonally different methicillin-resistant strains with defined macrolide-lincosamide-streptogramin B (MLS(B)) resistance phenotypes were tested. The novel ketolide exhibited broad-spectrum anti-staphylococcal activity against both methicillin-susceptible and methicillin-resistant strains. Apart from strains with constitutive expression of MLS(B) resistance, all staphylococcal strains tested were inhibited by < or = 0.063 mg/L of ABT-773, irrespective of the resistance phenotype for methicillin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751787     DOI: 10.1093/jac/49.1.189

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 2.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model.

Authors:  Suresh R Pai; Kavindra V Singh; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.